REGENXBIO Inc.
RGNXStock
$11.20+48.91%52W
Market Cap$581.60M
P/E—
Div yield—
Beta0.90
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-28.95%
Price vs S&P 500 (4W)76.46%
VGM Score41.08
Market Capitalization$581.60M
Earnings Surprise History
Q1 26-1.72est. -1.37
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RGNXREGENXBIO Inc. | C | F | C | $11.20 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Regenxbio is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. The company targets retinal, neuromuscular, and neurodegenerative diseases by delivering genes to cells to correct genetic defects or enable therapeutic protein production. Its pipeline addresses unmet medical needs in genetic and degenerative disorders.